Michele Manto
Private Equity Investor bei Xgen Venture Sgr SpA
Ursprung des Netzwerks ersten Grades von Michele Manto
| Einheit | Art der Einheit | Industrie | |
|---|---|---|---|
28
| Public Company | Biotechnology | 28 |
Xgen Venture Sgr SpA
 Xgen Venture Sgr SpA Investment ManagersFinance Xgen Venture Sgr SpA (XGEN Venture) is a venture capital firm founded in 2021 by Federica Draghi, Paolo Fundarò and Daniele Scarinci. The firm is headquartered in Milan, Italy.
10
| Private Company | Investment Managers | 10 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Michele Manto
| Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
|---|---|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member Chief Tech/Sci/R&D Officer | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal Chief Executive Officer | |
| INCYTE CORPORATION | Pharmaceuticals: Major | Director/Board Member | |
| MERCK KGAA | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| UNILEVER PLC | Household/Personal Care | Sales & Marketing | |
| SANOFI | Pharmaceuticals: Major | Director of Finance/CFO Corporate Officer/Principal | |
Advent Venture Partners LLP
 Advent Venture Partners LLP Investment ManagersFinance Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom. | Investment Managers | Private Equity Investor Private Equity Investor | |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Pharmaceuticals: Major | Chief Executive Officer | |
| IPSEN | Pharmaceuticals: Major | Director/Board Member | |
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Pharmaceuticals: Major | Director/Board Member Director/Board Member | |
| ALMIRALL, S.A. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer | |
Congenia Srl
 Congenia Srl Miscellaneous Commercial ServicesCommercial Services Congenia SRL operates as pharmaceutical company, is engaged in the development of novel therapeutics for diseases associated with mitochondrial stress-induced dysfunction. The company develops small molecule drugs that target the mitochondrial permeability transition pore, a protein channel with various macromolecular components that along with mitochondrial protein p66, appears to be associated with oxidative stress-induced cell death. The company was founded in 2004 by Saverio Minucci, Pier Giuseppe Pelicci, Marco Giorgio and Paolo Bernardi and is headquartered in Milan, Italy. | Miscellaneous Commercial Services | Corporate Officer/Principal Chief Operating Officer | |
Artax Biopharma, Inc.
 Artax Biopharma, Inc. Medical SpecialtiesHealth Technology Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA. | Medical Specialties | Director/Board Member Chairman | |
| NOVARTIS AG | Pharmaceuticals: Major | Investor Relations Contact | |
Novo Holdings AS (Denmark)
 Novo Holdings AS (Denmark) Financial ConglomeratesFinance Novo Holding A/S provides financial investments and manages the Novo Nordisk Foundation?s assets. It offers seed and venture capital to development stage companies and takes ownership positions in companies within life science and biotechnology. The company was founded on September 8, 1999 and is headquartered in Hellerup, Denmark. | Financial Conglomerates | Director/Board Member | |
Galapagos Biotech Ltd.
 Galapagos Biotech Ltd. BiotechnologyHealth Technology Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom. | Biotechnology | Director/Board Member Director/Board Member | |
Mogen International Nv
 Mogen International Nv Pharmaceuticals: OtherHealth Technology Part of AstraZeneca PLC, Mogen International Nv is a Dutch company that specializes in medicinal chemicals and botanical products. The company is based in Leiden, the Netherlands. Mogen International was acquired by Zeneca Group Plc on May 01, 1997 for $74.96 million. | Pharmaceuticals: Other | Corporate Officer/Principal Corporate Officer/Principal | |
| ENDOCYTE, INC. | Pharmaceuticals: Major | Director/Board Member | |
| Friedrich-Alexander University of Erlangen-Nuremberg | College/University | Doctorate Degree | |
| University of Leiden | College/University | Doctorate Degree | |
| Ghent University | College/University | Graduate Degree Graduate Degree | |
| Katholieke Universiteit Leuven | College/University | Doctorate Degree Graduate Degree Doctorate Degree Graduate Degree | |
| LIXTE BIOTECHNOLOGY HOLDINGS, INC. | Biotechnology | Chief Executive Officer | |
Avila Therapeutics, Inc.
 Avila Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Avila Therapeutics, Inc. researches and develops covalent drugs. The company was founded in 2007 and is headquartered in Summit, NJ. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
| DSM Life Sciences Products | Corporate Officer/Principal | ||
Genextra SpA
 Genextra SpA Investment ManagersFinance Genextra SpA (Genextra) is a venture capital firm founded in 2004 by Franceso Micheli and Saverio Minucci. The firm is headquartered in Milan, Italy. | Investment Managers | Chief Executive Officer Director/Board Member Private Equity Investor | |
University Hospital Antwerp
 University Hospital Antwerp Hospital/Nursing ManagementHealth Services University Hospital Antwerp provides clinical, patient care, academic training and scientific research services. The company was is headquartered in Belgium. | Hospital/Nursing Management | Director/Board Member | |
EryDel SpA
 EryDel SpA Medical SpecialtiesHealth Technology EryDel SpA offers medical research. It develops drugs and diagnostics delivered through human red blood cells via a medical device technology. The company was founded by Luigia Rossi and Mauro Magnani in 2007 and is headquartered in Bresso, Italy. | Medical Specialties | Director/Board Member Director/Board Member | |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Medical Specialties | Chairman | |
| Syngenta Mogen BV | Corporate Officer/Principal | ||
Tethis SpA
 Tethis SpA BiotechnologyHealth Technology Tethis SpA engages in the provision of nanobiotechnology solutions. It develops devices for liquid biopsy, molecular diagnostic, and proteomic and microbiology. The company was founded by Emanuele Barborini, Simone Vinati, and Massimo Gatelli in 2004 and is headquartered in Milan Italy. | Biotechnology | Chief Executive Officer Director/Board Member Chairman | |
| Wageningen University | College/University | Graduate Degree Graduate Degree | |
| Molecular Probes Europe BV | Corporate Officer/Principal Chief Executive Officer | ||
NeRRe Therapeutics Ltd.
 NeRRe Therapeutics Ltd. Medical DistributorsDistribution Services NeRRe Therapeutics Ltd. provides clinical and pre clinical drugs for treatment of neuronal hypersensitivity. It develops neurokinin receptor antagonists acquired from GlaxoSmithKline. The company was founded by Emiliangelo Ratti and Mike Trower in 2012 and is headquartered in Stevenage, the United Kingdom. | Medical Distributors | Director/Board Member Chief Executive Officer | |
VitalneXt BV
 VitalneXt BV Pharmaceuticals: GenericHealth Technology VitalneXt BV develops retails and manufactures products for healthy ageing. Its products include promanna, vital01 and other products. The firm develops products with evidence-based health benefits for the ageing population. It also develops new, proprietary, technologies, ingredients and products through its own network and through collaborations with the company's research partners. The company was founded by Rein Strijker in May 2013 and is headquartered in Amersfoort, the Netherlands. | Pharmaceuticals: Generic | Director/Board Member | |
Mimetas BV
 Mimetas BV BiotechnologyHealth Technology Mimetas BV develops organ-on-a-chip technology for testing of new medicines in high-throughput on miniaturized organ and disease models. It develops microfluidics-based culture plates that enable culturing and screening of a range of 3D organ and tissue models. The firm offers OrganoPlates microfluidics-based culture plates that serve as early stage screening models predicting toxic side effects and drug efficacy. The company was founded by Paul Vulto and Jos Joore in 2013 and is headquartered in Leiden, the Netherlands. | Biotechnology | Director/Board Member | |
miDIAGNOSTICS NV
 miDIAGNOSTICS NV Miscellaneous Commercial ServicesCommercial Services miDIAGNOSTICS NV develops a computer chip powered portable medical laboratory. The company is headquartered in Leuven, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
| RUBIUS THERAPEUTICS | Biotechnology | Director/Board Member | |
| thromboDx BV | Founder | ||
Drug Discovery & Development Solutions Ltd.
 Drug Discovery & Development Solutions Ltd. Miscellaneous Commercial ServicesCommercial Services Drug Discovery & Development Solutions Ltd. engages in the provision of financial services. The company is headquartered in Singapore. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Founder Chairman | |
CIBA Vision GmbH (Germany)
 CIBA Vision GmbH (Germany) Electronic ComponentsElectronic Technology Part of Alcon AG, CIBA Vision GmbH is a company based in Grosswallstadt, Germany. CIBA Vision GmbH manufactures and markets contact lenses. The German company was founded in 1983. The CEO is Norbert Dörr. | Electronic Components | Director/Board Member | |
InnovHeart Srl
 InnovHeart Srl Medical SpecialtiesHealth Technology InnovHeart Srl is a holding company, which engages in the development of transcatheter mitral valve replacement (TMVR) systems for the treatment of patients with mitral valve disease. It also develops Saturn Prosthesis, Transapical, and Transeptal systems that are designed to be consistent with the anatomy of the mitral valve. The company was founded by Giovanni Righini and is headquartered in Milan, Italy. | Medical Specialties | Chairman Director/Board Member Director/Board Member Director/Board Member | |
Sapreme Technologies BV
 Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | Biotechnology | Director/Board Member | |
Kuste Biopharma SAS
 Kuste Biopharma SAS Pharmaceuticals: MajorHealth Technology Kuste Biopharma SAS engages in the development of therapies for unmet medical inflammatory. The company was founded in 2019 and is headquartered in Lyon, France. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Director/Board Member | |
| Tibotec-Virco Comm Va | Corporate Officer/Principal | ||
| UZA Foundation | Director/Board Member |
Statistik
International
| Vereinigte Staaten | 13 |
| Niederlande | 12 |
| Belgien | 7 |
| Vereinigtes Königreich | 6 |
| Italien | 6 |
Sektoral
| Health Technology | 29 |
| Consumer Services | 6 |
| Finance | 4 |
| Commercial Services | 4 |
| Electronic Technology | 3 |
Operativ
| Director/Board Member | 179 |
| Corporate Officer/Principal | 74 |
| Independent Dir/Board Member | 43 |
| Chief Executive Officer | 37 |
| Chairman | 30 |
Am stärksten vernetzte Beziehungen
| Insiders | |
|---|---|
| Raj Bhikhu Parekh | 50 |
| Jérôme Contamine | 23 |
| Harrold van Barlingen | 20 |
| Simon Sturge | 20 |
| Daniel O'Day | 19 |
| Paolo Fundarò | 17 |
| Lena Elisabeth Svanberg | 16 |
| Katrine Bosley | 15 |
| Andre Hoekema | 14 |
| Bertil Lindmark | 14 |
| Howard Mitchell Rowe | 14 |
| Susanne Antonie Schaffert | 13 |
| Onno van de Stolpe | 13 |
| Paulus Stoffels | 11 |
| Piet Wigerinck | 11 |
- Börse
- Insiders
- Michele Manto
- Unternehmensverbindungen
